Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen M Colhoun, Per-Henrik Groop, Linong Ji, Niels Jongs, Chantal Mathieu, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Meike Brinker, Markus F. Scheerer, Julie Russell, Patrick Schloemer, Janet B. McGill
BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown. METHODS: of body-surface area), and albuminuria (urinary albumin-to-creatinine ratio [with albumin measured in milligrams and creatinine measured in grams], 200 to <5000) and were receiving an angiotensin-converting-enzyme (ACE) inhibitor or an angiotensin-receptor blocker. Participants were randomly assigned to receive finerenone (10 or 20 mg per day, depending on the eGFR) or matching placebo. The primary outcome was the relative change in the urinary albumin-to-creatinine ratio over a period of 6 months. RESULTS: ; 95% CI, -5.1 to -0.7); eGFR values approached baseline levels during the washout period. CONCLUSIONS: In adults with type 1 diabetes and CKD, finerenone resulted in a significantly greater decrease in the urinary albumin-to-creatinine ratio than placebo. (Funded by Bayer; FINE-ONE ClinicalTrials.gov number, NCT05901831.).